Phelix Therapeutics, LLC Awarded Phase I SBIR Grant from NIH to Develop Calpain Therapeutics for Idiopathic Pulmonary Fibrosis
Phelix Therapeutics, LLC is pleased to announce it has received a $201,665 grant from the National Institutes of Health (NIH). This Small Business Innovation Research (SBIR) funding will support Phelix’s continued research of Calpain therapeutics to inhibit myofibroblast generation in... - January 31, 2018
Press Releases 1 - 1 of 1